Abstract

The dopamine D2 agonist MCL-524 is selective for the D2 receptor in the high-affinity state (D2high), and, therefore, the PET analogue, [18F]MCL-524, may facilitate the elucidation of the role of D2high in disorders such as schizophrenia. However, the previously reported synthesis of [18F]MCL-524 proved difficult to replicate and was lacking experimental details. We therefore developed a new synthesis of [18F]MCL-524 using a "non-anhydrous, minimally basic" (NAMB) approach. In this method, [18F]F- is eluted from a small (10-12 mg) trap-and-release column with tetraethylammonium tosylate (2.37 mg) in 7:3 MeCN:H2O (0.1 mL), rather than the basic carbonate or bicarbonate solution that is most often used for [18F]F- recovery. The tosylated precursor (1 mg) in 0.9 mL anhydrous acetonitrile was added directly to the eluate, without azeotropic drying, and the solution was heated (150 °C/15 min). The catechol was then deprotected with the Lewis acid In(OTf)3 (10 equiv.; 150 °C/20 min). In contrast to deprotection with protic acids, Lewis-acid-based deprotection facilitated the efficient removal of byproducts by HPLC and eliminated the need for SPE extraction prior to HPLC purification. Using the NAMB approach, [18F]MCL-524 was obtained in 5-9% RCY (decay-corrected, n = 3), confirming the utility of this improved method for the multistep synthesis of [18F]MCL-524 and suggesting that it may applicable to the synthesis of other 18F-labeled radiotracers.

Highlights

  • Dopamine D2 receptor dysfunction is a hallmark of several neurological diseases and disorders, including schizophrenia, Parkinson’s disease, Tourette’s syndrome and addiction [1,2,3,4,5,6,7,8,9,10,11,12,13,14]

  • PET radiopharmaceuticals that can be used to measure differences in the population of D2 high versus D2 low may be useful in improving the understanding and diagnosis of these diseases [19,20,21,22]

  • Most PET probes of postsynaptic dopamine receptor function evaluated to date suffer from limitations that preclude their use for this application

Read more

Summary

Introduction

Dopamine D2 receptor dysfunction is a hallmark of several neurological diseases and disorders, including schizophrenia, Parkinson’s disease, Tourette’s syndrome and addiction [1,2,3,4,5,6,7,8,9,10,11,12,13,14]. Most PET probes of postsynaptic dopamine receptor function evaluated to date suffer from limitations that preclude their use for this application. The structurally related benzamide, [18 F]fallypride (Figure 1), does not distinguish between D2 and D3 [28], and the butyrophenone, Chemistry 2021, 3, FOR PEER REVIEW [11 C]methylspiperone (Figure 1), is not selective for D2 versus 5HT2 receptors [29]. All these radioligands are D which do not distinguish between radioligands areofD

Methods
Results
Discussion
Conclusion
Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call